Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Recommendation of “Buy” from Analysts

Replimune Group, Inc. (NASDAQ:REPL) has earned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $17.29.

A number of analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. JPMorgan Chase & Co. increased their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. BMO Capital Markets boosted their price target on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Friday, November 22nd. Finally, Jefferies Financial Group increased their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th.

Replimune Group Trading Up 0.5 %

Replimune Group stock opened at $12.62 on Wednesday. The business has a 50 day moving average price of $12.44 and a two-hundred day moving average price of $11.03. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The stock has a market cap of $863.42 million, a price-to-earnings ratio of -4.14 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, equities analysts forecast that Replimune Group will post -2.91 EPS for the current year.

Insider Buying and Selling

In other news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC lifted its position in Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after purchasing an additional 2,656,173 shares during the period. Braidwell LP lifted its holdings in Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after buying an additional 2,057,460 shares during the period. State Street Corp boosted its stake in Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after acquiring an additional 1,182,181 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after acquiring an additional 1,000,000 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in shares of Replimune Group by 45.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after acquiring an additional 238,747 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.